Pemivibart was well tolerated and prophylactic against COVID-19 infection among adult patients with significant immunocompromising conditions.

Theresa Gaffney is the lead Morning Rounds writer and reports on health care, new research, and public policy, with a ...

Key Points - GAAP revenue reached $0.85 million in Q2 2025, exceeding analyst estimates and Revenue more than doubled compared to Q2 2024, also exceeding analyst estimates. GAAP loss per share ...

TytoCare, a leading Israeli telemedicine company based in Netanya, is willing to work with Vietnamese regulators, insurers, ...

Childhood cancer survivors have a higher risk of developing severe COVID-19 than the general population, according to research published in The Lancet Regional Health: Europe.

Many people have recently questioned the relevance of the COVID vaccine. However new study shows that it has a positive ...

In a new paper, a team from Yale and Fred Hutch has found autoantibody reactivity could predict cancer patients' response to ...

Key Takeaways Cancer and its treatments can suppress the immune system, increasing risk of severe COVIDCOVID vaccine boosters ...

As the latest wave of COVID-19 shows no signs of abating, University of South Australia experts say it's not just booster ...

As the latest wave of COVID-19 shows no signs of abating, University of South Australia experts say it’s not just booster shots that could offer protection – healthy levels of vitamin D may also play ...

Researchers from Emory University and the CDC found that only 35% to 40% of pregnant and new parents plan to fully vaccinate their children. In other news: A shortened drug regimen for drug-resistant ...

While we have returned to many aspects of pre-pandemic life, the coronavirus has not completely disappeared.  Notably, cancer ...